Your browser doesn't support javascript.
loading
Yellow Fever Virus Genotyping Tool and Investigation of Suspected Adverse Events Following Yellow Fever Vaccination.
Rezende, Izabela Maurício de; Alves, Pedro Augusto; Arruda, Matheus Soares; Gonçalves, Andreza Parreiras; Oliveira, Gabriela Fernanda Garcia; Pereira, Leonardo Soares; Dutra, Maria Rita Teixeira; Campi-Azevedo, Ana Carolina; Valim, Valéria; Tourinho, Renata; Oliveira, Jaquelline Germano de; Calzavara, Carlos Eduardo; Said, Rodrigo Fabiano do Carmo; Kroon, Erna Geessien; Martins-Filho, Olindo Assis; Teixeira-Carvalho, Andrea; Drumond, Betânia Paiva.
  • Rezende IM; Departament of Microbiology, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, Minas Gerais, Brazil.
  • Alves PA; Instituto René Rachou/Fundação Oswaldo Cruz, 30190-002 Belo Horizonte, Minas Gerais, Brazil.
  • Arruda MS; Departament of Microbiology, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, Minas Gerais, Brazil.
  • Gonçalves AP; Instituto René Rachou/Fundação Oswaldo Cruz, 30190-002 Belo Horizonte, Minas Gerais, Brazil.
  • Oliveira GFG; Departament of Microbiology, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, Minas Gerais, Brazil.
  • Pereira LS; Departament of Microbiology, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, Minas Gerais, Brazil.
  • Dutra MRT; Hospital Eduardo de Menezes, Fundação Hospitalar do Estado de Minas Gerais, 30622-020 Belo Horizonte, Minas Gerais, Brazil.
  • Campi-Azevedo AC; Hospital Eduardo de Menezes, Fundação Hospitalar do Estado de Minas Gerais, 30622-020 Belo Horizonte, Minas Gerais, Brazil.
  • Valim V; Instituto René Rachou/Fundação Oswaldo Cruz, 30190-002 Belo Horizonte, Minas Gerais, Brazil.
  • Tourinho R; Hospital Universitário Cassiano Antônio Moraes - Empresa Brasileira de Serviços Hospitalares, Universidade Federal do Espírito Santo, 29075-910 Vitória, Espírito Santo, Brazil.
  • Oliveira JG; Biomanguinhos/Fundação Oswaldo Cruz, 21040-900 Rio de Janeiro, Rio de Janeiro, Brazil.
  • Calzavara CE; Instituto René Rachou/Fundação Oswaldo Cruz, 30190-002 Belo Horizonte, Minas Gerais, Brazil.
  • Said RFDC; Instituto René Rachou/Fundação Oswaldo Cruz, 30190-002 Belo Horizonte, Minas Gerais, Brazil.
  • Kroon EG; Secretaria de Estado de Saúde de Minas Gerais, 31630-900 Belo Horizonte, Minas Gerais, Brazil.
  • Martins-Filho OA; Departamento de Vigilância das Doenças Transmissíveis, Secretaria de Vigilância em Saúde, Ministério da Saúde, 70058-900 Brasília, Distrito Federal, Brazil.
  • Teixeira-Carvalho A; Departament of Microbiology, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, Minas Gerais, Brazil.
  • Drumond BP; Instituto René Rachou/Fundação Oswaldo Cruz, 30190-002 Belo Horizonte, Minas Gerais, Brazil.
Vaccines (Basel) ; 7(4)2019 Dec 04.
Article en En | MEDLINE | ID: mdl-31817103
The yellow fever (YF) vaccine consists of an attenuated virus, and despite its relative safety, some adverse events following YF vaccination have been described. At the end of 2016, Brazil experienced the most massive sylvatic yellow fever outbreak over the last 70 years and an intense campaign of YF vaccination occurred in Minas Gerais state in Southeast Brazil from 2016 to 2018. The present study aimed to develop a genotyping tool and investigate 21 cases of suspected adverse events following YF vaccination. Initial in silico analyses were performed using partial NS5 nucleotide sequences to verify the discriminatory potential between wild-type and vaccine viruses. Samples from patients were screened for the presence of the YFV RNA, using 5'UTR as the target, and then used for amplification of partial NS5 gene amplification, sequencing, and phylogenetic analysis. Genotyping indicated that 17 suspected cases were infected by the wild-type yellow fever virus, but four cases remained inconclusive. The genotyping tool was efficient in distinguishing the vaccine from wild-type virus, and it has the potential to be used for the differentiation of all yellow fever virus genotypes.
Palabras clave